WCLC 2022 | Sotorasib drug-drug interactions

The KRASG12C mutation is one of the most commonly occurring mutations in non-small cell lung cancer (NSCLC), occurring in 13% of lung adenocarcinomas. Sotorasib is a KRASG12C inhibitor which causes known drug-drug interactions that may lead to treatment inefficacy or serious side effects. Leila-Sophie Otten, PharmD, Radboud University Medical Centre, Radboud University Nijmegen, Netherlands, talks on an investigation into the need for physician guidance on drug-drug interactions to support safe and effective treatment with sotorasib in routine clinical practice. The most requested drug combinations form the Checker developed by RadboudUMC and University of Liverpool were determined. Next, their DDI potency was mapped by determining the DDI grading using an established grading system with a ‘traffic light’ classification. It was concluded that there is a clear clinical need for guidance on combining sotorasib with other medication. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.